Detalles de la búsqueda
1.
SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-480166
2.
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-450959
3.
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-444076
4.
B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-436620
5.
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-431897
6.
Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-463727
7.
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-452771
8.
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430003
9.
Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-474369
Resultados
1 -
9
de 9
1
Próxima >
>>